7m volume yesterday. Incredible |
Definitely and it has the best of both worlds having unrestricted access to the UK and the EU and the US has shown to always be willing to give a Belfast company a helpful and sympathetic ear if it's good for the economy. |
It's Belfast base makes FAB an ideal and easy choice for US, European or UK/Irish funds to allot seed funding to in this space, if they want to invest in life-science. Likewise with Government agencies. A small, but not to be underestimated, politico economic advantage. |
TLY looks good on paper but the difference between it and FAB is that the opportunities for FAB are endless or limitless whereas with TLY they are very dependent on Govt or NHS contracts and very susceptible to competitors. I'm not saying FAB isn't either but I believe FAB will be bought over in the short to medium term and at its current price its a sitting duck. |
PS,
I'm not saying FAB won't do well.
I'm saying the recent surge is largely by traders, pumpers/dumpers, who will obviously sell.
Look at the interims.
They had around £1.2m revenues.
Mcap is around £10m
I think the mcap being too high. They need significant news to justify it.
Look at TLY (Healthcare) - they recently announced £27m contract wins/extensions. They provide services to the NHS, inc Elective care to reduce the waiting lists.
Read any media news. NHS funding and plans are priority, inc using private sector.
Elective Care (surgery to reduce waiting times), NHS 111, Urgent Treatment centres, Physio services, Corportate Wellness services.
TLY's forecast fy2025(ends 31st March, same as FAB), revenue is £85m.
Mcap is £14m
The Labour govn are determined to reduce waiting times and have stated, inc today, that there will be greater use of private sector.
Take a look, feel free to counter any comments on there. No hundreds of trades to move the sp, no crowd... |
Trout,
Trader talk. Not something someone invested would do.
Obviously if there's hundreds of buys again then the share price will rise. It doesn't mean anything.
HVO shares still falling and the thread gone quiet. Why has the thread gone silent? It's mates with multiple ids working together, isn't it? |
MMs bidding for bundles again (675k) |
 PS,
"Nothing wrong with making money but your giving out on one hand it’s a pump and dump and yet here are you buying and selling like a typical pump and dump merchant."
I bought in clearly stating they are being pumped/dumped.
I sold whilst maintaining they are being pumped/dumped.
I backed my assertion that they are being pumped and dumped.
A p&d merchant wouldn't maintain a negative stance when they buy, would they?
I did exactly the same on Byot, bought in whilst maintaining they were being p&d and maintaining a negative stance. Now delisted, share price down 99.9%!!
Same on Trmr, sold at 844p, now 400p.
My posting history is there for all to see.
sikhthetech27 Jan '20 - 14:49 - 3973 of 4004 Edit
I bought some earlier...purely on the basis the Coronavirus will keep people interested and 1gw and his mates are pumping these....
Will look at selling before any TU...
Obviously 1gw won't be selling ANY as he's confident of a major deal closing soon, will you 1gw???
;-)
Then at 8p
sikhthetech - 17 Aug 2020 - 14:43:11 - 6666 of 8237 BYOTROL-CAN DELIVER AMAZING
I've now sold all mine today...
<...> |
Someone coming back in though, 14:18 looks like a chunky buy |
Looks like a small number of large (up to 100k shares) sells have knocked the FAB price, for the moment.
f |
You sold, you may now leave |
It's because of people like you that the share price is so volatile. You only bought last week and sold already. Again my assertion that you are a gambler and not an investor still stands.Nothing wrong with making money but your giving out on one hand it's a pump and dump and yet here are you buying and selling like a typical pump and dump merchant. |
It's being pumped on X by the usual crowd. |
Interims show cash as at 30th Sept was down to £400k
From their interims announced 6 weeks ago - they had only £400k cash as of Sept 2024.
Financial highlights
· Revenues of £1.2 million (H1 FY2024: £0.5 million)
· Expenditure on R&D maintained at £0.18 million (H1 FY2024: £0.18 million)
· Loss of £0.76 million (H1 FY2024: £1.4 million loss)
· Cash position in the bank at 30 September 2024 was £0.4 million (31 March 2024: £1.2 million) with a further £457k owed by existing debtors |
The Grant news was a month ago. The interims 2 months ago.
There's no company newsflow last week to justify the surge last week.
I maintain my assertion this is a pump/dump.
I sold mine earlier. |
A best-in-class antibody according to Novartis
Developed by FAB
Sold for $400m+ !
AMSTERDAM, the Netherlands, January 08, 2024 / B3C newswire / -- Calypso Biotech BV (‘Calypso̵7;), a leader in the development of Interleukin15 (IL-15) targeted therapies, announced today that it has entered into an agreement to be acquired by Novartis AG (‘NovartisR17;). Calypso’s shareholders will receive an upfront payment of $250 million upon closing and are eligible to receive development milestones of up to $175 million based on the achievement of certain predetermined milestones.
Calypso, a spin-out from Merck, is focused on the research and development of monoclonal antibodies for an array of autoimmune indications, with an expertise in IL-15 biology. IL-15 is a broad, untapped immune axis that controls barrier function and downstream immune cascades in many chronic autoimmune diseases. Calypso’s lead product candidate, CALY-002, is a potential best-in-class therapeutic antibody that binds to and neutralizes Interleukin-15.
The acquisition gives Novartis full rights to CALY-002. Novartis intends to further explore CALY-002 across a wide variety of autoimmune indications with high unmet medical need. CALY-002 is currently evaluated in a Phase 1b trial in patients with Celiac Disease and Eosinophilic Esophagitis.
Alain Vicari, Chief Executive Officer & Co-Founder, Calypso, commented: “We are excited for this transaction with Novartis, a company with relentless commitment to the development of innovative therapies for autoimmune conditions. As part of the Novartis portfolio, CALY-002 is in the best position to be developed effectively, so that it can promptly address unmet medical needs in multiple indications”
Bernard Coulie, Chairman, Calypso, commented: “The transaction with Novartis constitutes the high point in the development path of CALY-002 for the Calypso team. Calypso has established a significantly de-risked profile for CALY-002 as a potential best-in-class therapeutic anti-IL-15 antibody”
Richard Siegel, Head of Immunology Research at Novartis, commented: “Novartis is committed to bringing innovative treatment options forward for patients living with immunological diseases. We’re thrilled to add Calypso’s potential best-in-class antibody to our Immunology pipeline and explore it in a spectrum of autoimmune indications.” |
ShareSoc6 Jan '25 - 09:33 - 9 of 9
You can watch the recent webinar now on YouTube:
FAB's presentation from 27mins in... |
Some nonsense being posted. Read interim results - ceo advised cash breakeven and no need for funding. That was before they secured the 6m grant so there's no chance of any placing anytime soon. Wishful thinking for some |
A placing for what purpose exactly? Please enlighten us with your research that leads you to that conclusion and read the previous RNSs before you start claiming to know more than everyone else |
SikhTT if you judge a share price after 3 hours trading on a Monday morning then I don't believe share trading is for you. You need to judge the performance of a share over a week, month and ideally one year before you decide.To me you just come across as a gambler and not an investor so I'll not be paying much heed to your comments any longer. Best of luck |
Placing soon. |
Agreed pump and dump!! |
Nobody (sicktech etc) said much when it fell from £1 to 4p !!!! And now we only just back at 10p it’s a pump. I think not moron. Management have navigated FAB through the covid storm and the business is fundamentally undervalued. What you are seeing is a genuine re rate. There’s a lot of middle ground between 4p and £1. |
There you go, exactly as predicted.
Hundreds of trades again on no company newsflow.
There aren't hundreds of PI investors.
This is a pump/dump
Look at HVO/Polb, also pumped over the past year. Now threads gone quiet.
sikhthetech5 Jan '25 - 16:00 - 4462 of 4475 Edit
<...>
That's exactly my point. Hundreds of trades, grouped together and price rises substantially. Works both ways. |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
